Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AXT Inc (AXTI) vs Zoetis Inc (ZTS) Price & Performance

AXT IncTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

AXT Inc vs Zoetis Inc — how do they compare? AXT Inc trades at $54.01 (market cap $3.77B), while Zoetis Inc trades at $75.62 (market cap $31.05B). The key difference: Zoetis Inc is far larger — about 8.2× AXT Inc's market cap, and Zoetis Inc pays a 2.86% dividend while AXT Inc pays none. Which is the better fit depends on your goals.

AXTIZTS
Market Cap
$3.77B$31.05B
Sector
TechnologyHealth
52-Week High
$140.83$156.76
52-Week Low
$1.92$71.91
Enterprise Value
$3.73B$38.35B
Dividend Yield
2.86%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AXT Inc

AXTI trades at $50.46, down 11.8% in the past 24 hours, reflecting bearish technical signals and negative profitability metrics. The company reported a net loss of $21.26M in 2025 despite revenue of $88.33M, though 2026 projections show improved margins. Recent news highlights strong AI-driven demand for indium phosphide substrates and a $100M+ backlog, but export delays and cash flow risks remain concerns. Analyst consensus is bullish with 7 buy ratings, but technical indicators suggest near-term pressure.

The stock faces near-term headwinds from weak cash flow and high valuations (P/S 27.84), but long-term growth potential exists if AI demand materializes and capacity expansion executes smoothly. Key risks include geopolitical tensions affecting exports and execution challenges in scaling production. Investors should weigh the bullish analyst outlook against persistent fundamental weaknesses and technical bearishness.

Zoetis Inc

Zoetis (ZTS) trades at $75.39, down 0.22% with bearish technical signals and mixed sentiment. The company maintains strong fundamentals with $9.47B revenue, 28.03% net margin, and robust profitability metrics (ROE 67.75%, ROA 18.27%). Recent Q1 2026 earnings missed expectations, while multiple law firms have filed class action lawsuits alleging securities violations between January 2025 and May 2026.

Despite strong financials and analyst consensus price target of $101.43 (34.5% upside), ZTS faces significant legal risks and technical weakness. The stock presents a value opportunity for long-term investors willing to navigate near-term volatility, though the class action lawsuits create substantial uncertainty for shareholder value.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AXT Inc

AXT develops and manufactures high-performance compound semiconductor wafer substrates. Its products, like indium phosphide and gallium arsenide, are essential for data centers, 5G, and consumer electronics.

Read more on AXTI

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS